<DOC>
	<DOC>NCT01918033</DOC>
	<brief_summary>This is a study to evaluate the efficacy and safety of desloratadine (MK-4117) in Japanese participants with perennial allergic rhinitis. The primary hypothesis is that desloratadine is superior to placebo after 2 weeks of treatment with regard to change from baseline in Total Nasal Symptom Score among Japanese participants with perennial allergic rhinitis.</brief_summary>
	<brief_title>A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Desloratadine</mesh_term>
	<mesh_term>Histamine H1 Antagonists, Non-Sedating</mesh_term>
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<criteria>Diagnosed with perennial allergic rhinitis Outpatient. Lower respiratory tract infection or nasopharyngolaryngeal infection (acute upper respiratory tract infection, acute pharyngolaryngitis, or acute tonsillitis, etc.) Coexisting infections or systemic mycosis for which there are no effective antibiotics Asthma complication under treatment Nasal septum ulcers, nasal surgery, or nasal trauma, which has not healed Vasomotor rhinitis or eosinophilic rhinitis Nasal conditions (infectious sinusitis, hypertrophic rhinitis, acute or chronic rhinitis, nasal polyps, septal deviation, etc.) which may interfere with the evaluation of the efficacy of the study drug History of hypersensitivity to antihistamines or study drug Currently receiving treatment with another investigational drug or has received an investigational drug in the past 3 months Has started specific desensitization therapy or nonspecific allassotherapy (Histaglobin, vaccine therapy, etc.) or who had discontinued such therapies within 90 days (3 months) before the day of obtaining informed consent Severe hepatic, renal, cardiac, hematological disease, or other serious coexisting diseases and whose general condition is poor History of malignancy or clinically important hematological disorder History of severe drug allergy (e.g., anaphylactoid reaction).</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rhinitis</keyword>
	<keyword>Allergic Rhinitis</keyword>
	<keyword>Nose Diseases</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Cholinergic Antagonists</keyword>
	<keyword>Cholinergic Agents</keyword>
	<keyword>Neurotransmitter Agents</keyword>
	<keyword>Histamine H1 Antagonists, Non-Sedating</keyword>
	<keyword>Histamine H1 Antagonists</keyword>
	<keyword>Histamine Antagonists</keyword>
	<keyword>Histamine Agents</keyword>
</DOC>